Of chimps and men–finding the path to an HCV vaccine
✍ Scribed by Helmut M. Diepolder; Norbert H. Gruener; Jonathan Heeney
- Book ID
- 102243194
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 49 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
To define the early events that determine the outcome of acute hepatitis C virus (HCV) infection, we compared the course of viremia with the peripheral and intrahepatic T cell response and intrahepatic cytokine profile in six acutely infected chimpanzees. Three different outcomes were observed after peak viral titers were reached: sustained viral clearance, transient viral clearance followed by chronic infection, and chronic infection that persisted at initial peak titers. The results indicate that HCV spread outpaces the T cell response and that HCV rapidly induces but is not controlled by IFN-␣/; that viral clearance follows the entry and accumulation of HCV-specific IFN-gamma-producing T cells in the liver; and that it may not require the destruction of infected cells.
Comments
Chimpanzees are the only animal model for hepatitis C virus (HCV) infection. Similar to humans, self-limited as
📜 SIMILAR VOLUMES
**The best way to learn is to be engaged.**This book will engage you. Written as a conversation between Joe, Jason, and a number of funny fictional characters, this book will teach you everything you need to know about the paleo lifestyle in depth (not just the food aspect) and will entertai
**The best way to learn is to be engaged.** This book will engage you. Written as a conversation between Joe, Jason, and a number of funny fictional characters, this book will teach you everything you need to know about the paleo lifestyle in depth (not just the food aspect) and will enterta
## Abstract Three doses of a recombinant DNA HBV vaccine (MSD) were given to healthy male homosexuals. Seventy‐eight out of 104 (77.6%) participants had detectable antibody (anti‐HBs) two months after the third dose. Seroconversion occurred in only 9 out of 27 subjects (33.3%) who were anti‐HIV pos